Costs of PCSK9 inhibitors may be prohibitive

With the pending approval of two cholesterol-lowering drugs, the Washington Post reports concerns are mounting about the costs of the medications, which are both injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

The FDA is expected to approve alirocumab (Praluent, Regeneron Pharmaceuticals and Sanofi Aventis) by July 24. The other PCSK9 inhibitor, evolocumab (Repatha, Amgen), is expected to be approved by Aug. 27. In June, FDA advisory committees recommended approval of both drugs. For more, check out the link below: